(Q47913355)

6 February 2018

title

Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma (English)

1 reference

6 February 2018

0 references

Kuittinen T

1

1 reference

6 February 2018

Nousiainen T

2

1 reference

6 February 2018

Halonen P

3

1 reference

6 February 2018

Mahlamäki E

4

1 reference

6 February 2018

Jantunen E

5

1 reference

6 February 2018

language of work or name

English

0 references

publication date

1 May 2004

1 reference

6 February 2018

Bone Marrow Transplantation

published in

1 reference

6 February 2018

volume

33

1 reference

6 February 2018

issue

9

1 reference

6 February 2018

page(s)

907-912

1 reference

6 February 2018

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1704466

exact match

0 references

cites work

Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704466

Economic considerations in the use of peripheral blood progenitor cells to support high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704466

The whys and hows of hematopoietic progenitor and stem cell mobilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704466

Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704466

Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphom

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704466

Cyclophosphamide, etoposide and G-CSF to mobilize peripheral blood stem cells for autologous stem cell transplantation in patients with lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704466

Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704466

Management strategies for the hard-to-mobilize patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704466

It's moving day: factors affecting peripheral blood stem cell mobilization and strategies for improvement [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704466

Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704466

Hematopoietic stem cell transplantation activity in Europe 1999

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704466

7 January 2021

Current trends in hematopoietic stem cell transplantation in Europe

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704466

7 January 2021

Optimum methods to mobilize stem cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704466

7 January 2021

Peripheral blood stem cell mobilization using high-dose cyclophosphamide and G-CSF in pretreated patients with lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704466

7 January 2021

Characterization and outcome of "hard to mobilize"' lymphoma patients undergoing autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704466

7 January 2021

Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34+ cell content

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704466

7 January 2021

Factors that influence collection and engraftment of autologous peripheral-blood stem cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704466

7 January 2021

Progenitor cell yields are frequently poor in patients with histologically indolent lymphomas especially when mobilized within 6 months of previous chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704466

7 January 2021

Hemopoietic progenitor cell mobilization and harvest following an intensive chemotherapy debulking in indolent lymphoma patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704466

7 January 2021

Analysis of the effect of prior therapy on progenitor cell yield: use of a chemotherapy scoring system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704466

7 January 2021

Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704466

7 January 2021

Is chemotherapy scoring useful to predict progenitor cell mobilisation in patients with non-Hodgkin's lymphoma?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704466

7 January 2021

Broad inter‐individual variations in circulating progenitor cell numbers induced by granulocyte colony‐stimulating factor therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704466

7 January 2021

Scoring system for the prediction of successful peripheral blood stem cell (PBSC) collection in non-Hodgkin's lymphoma (NHL): application in clinical practice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704466

7 January 2021

Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704466

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1704466

1 reference

6 February 2018

1 reference

6 February 2018